This news release constitutes a "designated
news release" for the purposes of the Company's prospectus
supplement dated September 25, 2023
to its short form base shelf prospectus dated June 27, 2023.
VANCOUVER, BC, Feb. 1, 2024
/CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company")
(TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing
traditional and innovative behavioral health treatments with a
focus on safe, evidence-based psychedelic-assisted therapies,
announces today that it has entered into an agreement to divest its
holdings in Alto Neuroscience Inc. ("Alto"), a clinical-stage
biopharmaceutical company. The Alto investment was included in the
Company's acquisition of Novamind Inc. on June 10, 2022. Alto has recently announced the
terms for its IPO and listing on the New York Stock Exchange.
"We are happy to announce this divestiture as we continue to
focus on our core business and drive shareholder value creation
more broadly," said Payton
Nyquvest, Numinus Founder and CEO. "As our core strategy is
to build the critical infrastructure that addresses the growing
need for effective mental health treatments, the proceeds from the
sale of this non-core asset will provide additional financial
liquidity and flexibility. Our continued focus on driving
growth and optimizing operations will enable us to apply these
funds efficiently while the management team remains focused on
achieving profitability with our continuing operations."
About Numinus Wellness
Numinus Wellness Inc. (TSX: NUMI) helps people to heal and be well
through the development and delivery of innovative mental health
care and access to safe, evidence-based psychedelic-assisted
therapies. The Numinus model – including psychedelic research and
clinic care – is at the forefront of a transformation aimed at
healing rather than managing symptoms for depression, anxiety,
trauma, pain and substance use. At Numinus, we are leading the
integration of psychedelic-assisted therapies into mainstream
clinical practice and building the foundation for a healthier
society.
Learn more at www.numinus.com and follow us
on LinkedIn, Facebook, Twitter,
and Instagram.
Forward-Looking Statements
Statements and other information contained in this press
release about anticipated future events constitute forward-looking
statements. Forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate",
"believe", "plan", "estimate", "expect" and "intend" and statements
that an event "may", "will", "should", "could" or "might" occur or
other similar expressions. Forward-looking statements are subject
to risks and uncertainties and other factors that could cause
actual results to differ materially from those contained in the
forward-looking statements, including but not limited to potential
delays in closing of the sale, if at all; the ability to deploy net
proceeds from this or any future divestitures in the manner and
timeframe we anticipate, if at all; and other economic, business,
competitive and/or regulatory factors affecting our business
generally including the risks set forth in the Company's annual
information form dated November 29,
2023, and available on SEDAR+ at www.sedarplus.com.
Forward-looking statements are based on estimates and opinions of
management at the date the statements are made. The Company does
not undertake any obligation to update forward-looking statements
even if circumstances or management's estimates or opinions should
change except as required by applicable laws. Investors should not
place undue reliance on forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/numinus-wellness-divests-of-holdings-in-alto-neuroscience-inc-302050176.html
SOURCE Numinus Wellness Inc.